Intervention Protocol

Minocycline for amyotrophic lateral sclerosis or motor neuron disease

  1. Sivakumar Sathasivam1,*,
  2. Robert Addison-Jones2,
  3. Robert G Miller3,
  4. Dan H Moore4,
  5. Carolyn A Young5

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 17 OCT 2007

DOI: 10.1002/14651858.CD006840


How to Cite

Sathasivam S, Addison-Jones R, Miller RG, Moore DH, Young CA. Minocycline for amyotrophic lateral sclerosis or motor neuron disease (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006840. DOI: 10.1002/14651858.CD006840.

Author Information

  1. 1

    The Walton Centre for Neurology and Neurosurgery, Neurology Department, Liverpool, UK

  2. 2

    Royal Preston Hospital, Ward 17, Department of Neurology, Preston, UK

  3. 3

    California Pacific Medical Center, Forbes Norris ALS Research Center, San Francisco, USA

  4. 4

    California Pacific Medical Center, Research Institute, San Francisco, CA, USA

  5. 5

    The Walton Centre for Neurology and Neurosurgery, Liverpool, UK

*Sivakumar Sathasivam, Neurology Department, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, L9 7LJ, UK. sivakumar.sathasivam@thewaltoncentre.nhs.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 OCT 2007

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

We will systematically review the evidence from randomised trials for the benefits and harms from minocycline for ALS or MND.